Business Context and Reporting Period
This Form 8-K Current Report was filed by Rocket Pharmaceuticals, Inc. (RCKT) on March 11, 2022, covering events occurring on March 7, 2022, and March 10, 2022. The filing details significant changes to the Company's Board of Directors and executive leadership team.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on corporate governance and personnel changes.
Material Changes
Appointment of Director
- Individual: Fady Malik, M.D., Ph.D.
- Effective Date: March 10, 2022.
- Compensation: Granted options to purchase 33,199 shares (vesting monthly over 3 years) and 8,641 shares (vesting in full after 1 year) at the closing market price on the grant date.
- Background: Dr. Malik is a cardiologist with extensive experience in drug development, having served as Executive Vice President of Research and Development at Cytokinetics, Inc. since 2015.
Resignation of Chief Financial Officer
- Individual: Carlos Garcia-Parada.
- Effective Date: March 16, 2022.
- Reason: Personal reasons.
- Transition: Mr. Garcia-Parada will serve as an advisor until March 31, 2022.
Appointment of Interim Principal Financial Officer
- Individual: John Militello.
- Current Roles: Vice President – Finance, Senior Controller, Treasurer, and Principal Accounting Officer.
- Effective Date: March 16, 2022 (coinciding with the CFO resignation).
- Background: Mr. Militello is a Certified Public Accountant who joined Rocket Pharmaceuticals in January 2018.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, outlook, or management commentary regarding business operations. No new risks or contingencies were disclosed in this report. The Company confirmed there are no related person transactions or family relationships involving the new director or interim officer that would constitute a conflict of interest.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the stock options granted to new Director Fady Malik.
- Monitor the Company's announcement for the permanent appointment of a Chief Financial Officer to replace the interim arrangement.
- Review the Company's upcoming proxy statement for details on Dr. Malik's nomination for election at the 2022 annual meeting of stockholders.
- Confirm the transition plan for financial reporting responsibilities during the interim period under John Militello.